Drug Profile
SelK 2
Alternative Names: Anti P-selectin glycoprotein ligand-1; Anti-PSGL-1-mAb - Tetherex; SelK-2Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator Selexys Pharmaceuticals
- Developer Tetherex Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antithrombotics; Monoclonal antibodies
- Mechanism of Action P-selectin ligand protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Chronic obstructive pulmonary disease; Venous thromboembolism
- No development reported Crohn's disease
- Discontinued Multiple myeloma
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Crohn's-disease in USA (Parenteral)
- 29 Jun 2020 Phase-II clinical trials in Asthma in United Kingdom (IV) (EudraCT2020-001027-13)
- 29 Jun 2020 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (IV) (EudraCT2020-001027-13)